VD
Vamil Divan Guggenheim Latest Price Targets & Analyst Ratings
# | Stock | Price | Price Target |
Upside Downside | Rating | Date | |
---|---|---|---|---|---|---|---|
1 |
1
AbbVie
ABBV
$375B
| $212.51 | $227 |
7%
upside
| Buy | 1 month ago |
|
2 |
2
Johnson & Johnson
JNJ
$430B
| $178.38 | $167 |
6%
downside
| Neutral | 1 month ago |
|
3 |
3
ProKidney
PROK
$304M
| $2.25 | $7 |
211%
upside
| Buy | 1 month ago |
|
4 |
JBIO
4
Jade Biosciences, Inc. Common Stock
JBIO
$253M
| $7.76 | $14 |
80%
upside
| Buy | 2 months ago |
|
5 |
5
Savara
SVRA
$641M
| $3.71 | $8 |
116%
upside
| Buy | 3 months ago |
|
6 |
6
Amgen
AMGN
$153B
| $283.55 | $288 |
2%
upside
| Neutral | 3 months ago |
|
7 |
7
ANI Pharmaceuticals
ANIP
$2.07B
| $95.37 | $86 |
10%
downside
| Buy | 3 months ago |
|
8 |
VALN
8
Valneva
VALN
$742M
| $8.64 | $14 |
62%
upside
| Buy | 4 months ago |
|
9 |
9
Merck
MRK
$212B
| $84.71 | $115 |
36%
upside
| Buy | 4 months ago |
|
10 |
10
Travere Therapeutics
TVTX
$1.93B
| $21.66 | $47 |
117%
upside
| Buy | 4 months ago |
|
11 |
11
Absci
ABSI
$368M
| $2.46 | $10 |
307%
upside
| Buy | 5 months ago |
|
12 |
12
Vera Therapeutics
VERA
$1.55B
| $24.21 | $61 |
152%
upside
| Buy | 6 months ago |
|
13 |
13
Insmed
INSM
$30.7B
| $145.12 | $101 |
30%
downside
| Buy | 6 months ago |
|
14 |
14
Acadia Pharmaceuticals
ACAD
$4.26B
| $25.26 | $19 |
25%
downside
| Neutral | 3 years ago |
|
15 |
15
Neurocrine Biosciences
NBIX
$14.3B
| $144.13 | $98 |
32%
downside
| Neutral | 3 years ago |
|
16 |
16
Alkermes
ALKS
$4.94B
| $29.94 | $34 |
14%
upside
| Buy | 3 years ago |
|
17 |
17
Axsome Therapeutics
AXSM
$6.25B
| $125.20 | $49 |
61%
downside
| Buy | 3 years ago |
|
18 |
18
Eli Lilly
LLY
$652B
| $726.81 | $356 |
51%
downside
| Buy | 3 years ago |
|
19 |
19
Xeris Biopharma Holdings
XERS
$1.27B
| $7.87 | $6 |
24%
downside
| Buy | 3 years ago |
|
20 |
20
Biohaven
BHVN
$1.68B
| $15.86 | $154 |
871%
upside
| Buy | 3 years ago |
|
21 |
21
AbbVie
ABBV
$375B
| $212.51 | $166 |
22%
downside
| Buy | 3 years ago |
|
22 |
22
Pfizer
PFE
$142B
| $24.89 | $56 |
125%
upside
| Neutral | 3 years ago |
|
23 |
23
Evolus
EOLS
$496M
| $7.67 | $15 |
96%
upside
| Buy | 4 years ago |
|